Analyst Price Targets — WVE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 12:06 pm | — | Wells Fargo | $27.00 | $13.27 | TheFly | Wave Life Sciences price target lowered to $27 from $29 at Wells Fargo |
| February 3, 2026 11:23 am | — | Canaccord Genuity | $43.00 | $13.43 | TheFly | Wave Life Sciences price target raised to $43 from $40 at Canaccord |
| February 2, 2026 6:16 pm | Michael Freeman | Raymond James | $26.00 | $13.43 | StreetInsider | Raymond James: 'WVE regains full economic rights to WVE-006 from GSK' |
| December 19, 2025 3:39 pm | Andrew Fein | H.C. Wainwright | $30.00 | $16.57 | TheFly | Wave Life Sciences price target raised to $30 from $22 at H.C. Wainwright |
| December 16, 2025 12:38 pm | — | UBS | $32.00 | $16.11 | TheFly | Wave Life Sciences price target raised to $32 from $24 at Oppenheimer |
| December 16, 2025 11:06 am | Cheng Li | Oppenheimer | $32.00 | $16.98 | StreetInsider | WAVE Life Sciences (WVE) PT Raised to $32 at Oppenheimer |
| December 15, 2025 12:35 pm | — | Truist Financial | $50.00 | $16.61 | TheFly | Wave Life Sciences price target raised to $50 from $36 at Truist |
| December 12, 2025 11:47 am | Yun Zhong | Wedbush | $33.00 | $16.74 | TheFly | Wedbush raises price target on Wave Life Sciences, adds to Best Ideas List |
| December 9, 2025 12:59 pm | Steve Seedhouse | Cantor Fitzgerald | $34.00 | $19.27 | TheFly | Wave Life Sciences price target raised to $34 from $12 at Cantor Fitzgerald |
| December 9, 2025 11:48 am | — | Wells Fargo | $29.00 | $18.52 | TheFly | Wave Life Sciences price target raised to $29 from $16 at Wells Fargo |
Latest News for WVE
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for WVE.
U.S. House Trading
No House trades found for WVE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.